Streetbeat News

Regulatory

DM

NNDM

Desktop Metal stockholders have approved a merger with Nano Dimension, with the transaction expected to close in Q4 2024 pending regulatory approvals. 60% of outstanding DM shares voted, with over 96% in favor.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:32 am

ZVIA

Zevia PBC has regained compliance with the New York Stock Exchange's minimum stock price continued listing standard, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:10 am

RNA

Avidity Biosciences announced that the FDA has removed the partial clinical hold on Delpacibart Etedesiran (Del-Desiran/AOC 1001), an investigational treatment for Myotonic Dystrophy Type 1. This development allows the company to proceed with its clinical trials.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:06 am

IONS

Ionis Pharmaceuticals is set to present new three-year data from its Phase 2 open-label extension study and additional results from the Phase 3 OASIS and OASISplus studies of Donidalorsen for Hereditary Angioedema at the 2024 ACAAI Annual Scientific Meeting.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:06 am

ALDX

Aldeyra Therapeutics has resubmitted a New Drug Application to the FDA for its investigational drug, Reproxalap, aimed at treating dry eye disease. This marks a significant step in the drug's approval process.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:03 am

AZN

The FDA has accepted and granted priority review to AstraZeneca's supplemental new drug application for Calquence (Acalabrutinib) for previously untreated mantle cell lymphoma. The FDA action date is anticipated during Q1 of 2025.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 9:33 am

BTC-USD

SWIFT plans to trial live digital currency transactions in 2025, aiming to integrate digital currencies and tokenized assets into the mainstream financial system. This move aligns with global central banks' exploration of CBDCs, despite some controversy.

Portfolio Pulse from Benzinga Neuro

October 03, 2024 | 9:07 am

INTC

MSFT

MU

NVDA

President Biden signed a law exempting certain U.S. chipmaking facilities from federal environmental reviews under the CHIPS Act, aiming to prevent delays in semiconductor projects. This impacts companies like Intel, Micron, and Samsung, which are receiving substantial government subsidies.

Portfolio Pulse from Benzinga Neuro

October 03, 2024 | 8:13 am

ABVX

Abivax has reported positive interim results for its drug Obefazimod, showing efficacy and safety in treating moderate to severe ulcerative colitis over a two-year period. The drug maintained clinical remission and was well-tolerated with no new safety concerns.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 7:08 am

AAPL

Apple's supplier responsibility team visited Tata Electronics' facility in Tamil Nadu after a fire incident to provide counsel and advice. The fire caused minor injuries and halted production. A government investigation is underway to assess safety for resuming operations.

Portfolio Pulse from Nivedita Hazra

October 03, 2024 | 6:49 am